Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AT-301B · 1 trial · 1 indication
incidence of abnormal ECG Change from baseline in clinical laboratory parameters * Change from baseline in vital signs parameters * Change from baseline in 12-lead ECGs * Change from baseline in physical examination findings including auscultation * Change from baseline in oxygen saturation
incidence of abnormal sounds Change from baseline in clinical laboratory parameters * Change from baseline in vital signs parameters * Change from baseline in 12-lead ECGs * Change from baseline in physical examination findings including auscultation * Change from baseline in oxygen saturation
Incidence of abnormal oxygen saturation Change from baseline in clinical laboratory parameters * Change from baseline in vital signs parameters * Change from baseline in 12-lead ECGs * Change from baseline in physical examination findings including auscultation * Change from baseline in oxygen saturation
incidence of abnormal ranges Change from baseline in clinical laboratory parameters * Change from baseline in vital signs parameters * Change from baseline in 12-lead ECGs * Change from baseline in physical examination findings including auscultation * Change from baseline in oxygen saturation
incidence of abnormal measures Change from baseline in clinical laboratory parameters * Change from baseline in vital signs parameters * Change from baseline in 12-lead ECGs * Change from baseline in physical examination findings including auscultation * Change from baseline in oxygen saturation
| Arm | Type | Description |
|---|---|---|
| AT-301B | ACTIVE_COMPARATOR | AT-301B consists of edetate disodium, glyceryl monooleate, polysorbate 80, benzalkonium chloride, microcrystalline cellulose and sodium carboxymethylcellulose (vivapur), trisodium citrate dihydrate, and purified water (HCl to adjust pH to 5.0) |
| AT-301A | PLACEBO_COMPARATOR | AT-301A consists of sodium chloride, benzalkonium chloride and purified water (NaOH/HCl to adjust pH to 5.0) |
| Name | Type | Description |
|---|---|---|
| AT-301B | DRUG | Nasal Spray |
| AT-301A | DRUG | Nasal Spray |
Inclusion Criteria: Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects 2. Adult males and females, 18 to 64 years of age (inclusive) at the...
AT-301B is an investigational small molecule being developed by Atossa Therapeutics, Inc. It is in Phase 1 clinical development. Atossa Therapeutics trades on the Nasdaq under the ticker ATOS. The specific disease indications for AT-301B have not been publicly disclosed.
AT-301B is being developed by Atossa Therapeutics, Inc., a biopharmaceutical company that trades on the Nasdaq under the ticker symbol ATOS. Atossa Therapeutics is the sponsor of the clinical program for AT-301B.
AT-301B is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial of AT-301B has been completed, and no active trials of AT-301B are currently listed.
AT-301B has been studied in one completed Phase 1 trial, NCT04519788, titled AT-301 Nasal Spray in Healthy Adults. The trial enrolled 32 healthy adult volunteers in Australia, was randomized, double-blind, and placebo-controlled, and included participants aged 18 years and older.
No. AT-301B is an investigational drug in Phase 1 clinical development and is not FDA approved. Its only completed trial, NCT04519788, was a Phase 1 study in healthy adult volunteers conducted in Australia.